公开(公告)号：US11633399B2

公开(公告)日：2023-04-25

申请号：US16737503

申请日：2020-01-08

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Moshe Arkin ,  Marcel Zighelboim ,  Ori Nov ,  Ofer Toledano ,  Karine Neimann

IPC: A61K31/505 ,  A61K31/517 ,  A61K31/5377 ,  A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61K31/05 ,  A61K9/06 ,  A61K31/506

Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

公开(公告)号：US11426378B2

公开(公告)日：2022-08-30

申请号：US16794887

申请日：2020-02-19

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Ori Nov ,  Vered Ram

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/107 ,  A61K9/00 ,  A61K9/06 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in the pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75%.

公开(公告)号：US10933046B2

公开(公告)日：2021-03-02

申请号：US16794839

申请日：2020-02-19

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Ori Nov ,  Vered Ram

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.

公开(公告)号：US10702493B2

公开(公告)日：2020-07-07

申请号：US16514033

申请日：2019-07-17

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Ofer Toledano ,  Ori Nov

IPC: A61K31/203 ,  A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/50

Abstract: The present application is directed to regimens, methods of treatment, and compositions for the treatment of acne in a subject suffering therefrom.

公开(公告)号：US20190015369A1

公开(公告)日：2019-01-17

申请号：US15978146

申请日：2018-05-13

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Moshe Arkin ,  Stephen Cherkez ,  Ofer Toledano

IPC: A61K31/203 ,  A61K47/14 ,  A61K9/50 ,  A61K31/327 ,  A61K9/00

Abstract: The present disclosure relates to methods of treatment of acne in a patient in need thereof, comprising the concomitant once daily topical administration of from about 20 w/w to about 10% w/w of solid particulate benzoyl peroxide (BPO) and from about 0.01% w/w to about 0.1% w/w of solid particulate all trans retinoic acid (ATRA) for a period of up to 3 months, wherein the side-effects of the two actives are medically acceptable and wherein the therapeutic effect of BPO and ATRA is superior to the effect of each active administered alone. The concomitant administration may be carried out by once daily administration to a patient in need thereof of a single composition or of a first composition comprising BPO and a second composition comprising ATRA from a dual chamber dispenser or from two separate dispensers, mixed before applying on the skin of a patient in need thereof for up to 2 weeks, up to 1 month, preferably up to 2 months and more preferably up to 3 months.

公开(公告)号：US09687465B2

公开(公告)日：2017-06-27

申请号：US13686533

申请日：2012-11-27

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Hanan Sertchook ,  Ofer Toledano ,  Haim Bar-Simantov

IPC: A61K31/327 ,  A61K9/00 ,  A61K47/10 ,  A61K47/14 ,  A61K9/107 ,  A61K9/50

CPC classification number: A61K31/165 ,  A61K9/00 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/1075 ,  A61K9/501 ,  A61K31/192 ,  A61K31/327 ,  A61K31/704 ,  A61K31/7052 ,  A61K31/7056 ,  A61K47/10 ,  A61K47/14 ,  A61K2300/00

Abstract: The present invention relates to pharmaceutical compositions for topical use (including also dermatological compositions), for treating skin conditions and afflictions, such as rosacea and symptoms and conditions associated there from.